Evidence map›Paper›PMID 35508636›Full record

ArticleScientific reports2022

Discovery of first-in-class nanomolar inhibitors of heptosyltransferase I reveals a new aminoglycoside target and potential alternative mechanism of action.

Jozafina Milicaj, Bakar A Hassan, Joy M Cote, Carlos A Ramirez-Mondragon, Nadiya Jaunbocus, Angelika Rafalowski, Kaelan R Patel, Colleen D Castro, Ramaiah Muthyala, Yuk Y Sham and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. StandardisedFrontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jozafina Milicaj *Department of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Bakar A Hassan *Department of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Joy M CoteDepartment of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Carlos A Ramirez-MondragonBioinformatics and Computational Biology Program, University of Minnesota, Minneapolis, MN, 55455, USA.
Nadiya JaunbocusDepartment of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Angelika RafalowskiDepartment of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Kaelan R PatelDepartment of Integrative Biology and Physiology, Medical School, University of Minnesota, Minneapolis, MN, 55455, USA.
Colleen D CastroDepartment of Chemistry, Wesleyan University, Middletown, CT, 06459, USA.
Ramaiah MuthyalaDepartment of Experimental and Clinical Pharmacology, College Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Yuk Y ShamDepartment of Integrative Biology and Physiology, Medical School, University of Minnesota, Minneapolis, MN, 55455, USA. shamx002@umn.edu.
Erika A TaylorDepartment of Chemistry, Wesleyan University, Middletown, CT, 06459, USA. eataylor@wesleyan.edu.
Wesleyan University · USUniversity of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Inhibition of HeptosyltransferaseI for the treatment of Gram-negative bacterial infectionR15AI119907 · NIAID · WESLEYAN UNIVERSITY · PI TAYLOR, ERIKA A · 2015 to 2015
$493k
NIAID NIH HHS R15 AI119907NIH HHS 1R15AI119907-01
6 · The paper itself

Abstract

A clinically relevant inhibitor for Heptosyltransferase I (HepI) has been sought after for many years because of its critical role in the biosynthesis of lipopolysaccharides on bacterial cell surfaces. While many labs have discovered or designed novel small molecule inhibitors, these compounds lacked the bioavailability and potency necessary for therapeutic use. Extensive characterization of the HepI protein has provided valuable insight into the dynamic motions necessary for catalysis that could be targeted for inhibition. Structural inspection of Kdo

Indexed as

AminoglycosidesLipopolysaccharidesAnti-Bacterial AgentsGlycosyltransferasesAminoglycosidesAnti-Bacterial AgentsGlycosyltransferasesheptosyltransferaseLipopolysaccharides

Identifiers

PMID35508636
PMCPMC9068772
OpenAlexW4225376285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.